Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)

NCT05953337 is registered in ClinicalTrials.gov with ABK Biomedical as lead sponsor.

NCT NCT05953337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05953337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Lead sponsor
ABK Biomedical
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 21, 2023
Completion date
February 28, 2027
Enrollment
120 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, hepatocellular carcinoma non-resectable, liver cancer